Certara Inc. Common Stock (CERT)
Stock · NASDAQ · Technology
$9.37as of 10/16/2026
Price chart
Active signals
CERT Signal Track Record
How signals performed across all stocks →What CERT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | +3.0% | 61% | September 16, 2026 |
| Bollinger Band Breakout | 23 | -0.8% | 48% | October 5, 2026 |
| Bollinger Band Breakdown | 23 | -1.8% | 48% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -0.9% | 40% | October 31, 2025 |
| Any 20-session window (baseline) | -0.9% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CERT
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp…
- Sector
- Technology
- Industry
- Computer Software: Prepackaged Software
- Employees
- 1,515
- Website
- www.certara.com/
Fundamentals
- 1-day range
- $8.64$9.27
- Market cap
- $1.24B
- P/E (trailing)
- —
- P/E (forward)
- 23.43
- EPS (trailing)
- $-0.44
- Dividend yield
- —
- Beta
- 1.29
- Avg. volume
- 3.09M
How Certara Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
Certara Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CERTCertara Inc. Common Stock$9.37▼ 3.00%Market cap $1.24BP/E —$4.45$13.12
- GTMZoomInfo Technologies Inc Common Stock$3.8▼ 6.86%Market cap $1.22BP/E —$2.54$12.31
- SBETSharplink Inc. Common Stock$7.57▼ 7.46%Market cap $1.34BP/E —$4.46$16.2
- BLZEBackblaze Inc. Class A Common Stock$8.6▼ 13.22%Market cap $1.12BP/E —$3.26$23.99
- LSPDLightspeed Commerce Inc. Subordinate Voting Shares$10.57▼ 2.94%Market cap $1.36BP/E —$10.8$19.25
- TUYATuya Inc. American Depositary Shares each representing one Class A Ordinary Share$1.65▼ 3.51%Market cap $1.08BP/E 15.24$1.6$2.61
- RCATRed Cat Holdings Inc. Common Stock$4.72▼ 3.67%Market cap $1.06BP/E —$4.41$18.78
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CERT Certara Inc. Common Stock | $1.24B | — | $9.37 | ▼ 3.00% | $4.45$13.12 |
| GTM ZoomInfo Technologies Inc Common Stock | $1.22B | — | $3.8 | ▼ 6.86% | $2.54$12.31 |
| SBET Sharplink Inc. Common Stock | $1.34B | — | $7.57 | ▼ 7.46% | $4.46$16.2 |
| BLZE Backblaze Inc. Class A Common Stock | $1.12B | — | $8.6 | ▼ 13.22% | $3.26$23.99 |
| LSPD Lightspeed Commerce Inc. Subordinate Voting Shares | $1.36B | — | $10.57 | ▼ 2.94% | $10.8$19.25 |
| TUYA Tuya Inc. American Depositary Shares each representing one Class A Ordinary Share | $1.08B | 15.24 | $1.65 | ▼ 3.51% | $1.6$2.61 |
| RCAT Red Cat Holdings Inc. Common Stock | $1.06B | — | $4.72 | ▼ 3.67% | $4.41$18.78 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 'HHS launches project to speed up clinical trials' - AxiosBenzinga · 9/30/2026
- In-Silico Drug Discovery Market Report Now Available: Capitalize on AI-led R&D disruption as revenue surges from $3.3B to $6B by 2030; benchmark Certara, Insilico Medicine, Isomorphic Labs, Exscientia and BenevolentAI to secure share.Yahoo · 9/30/2026
- UBS Downgrades Certara to Neutral, Maintains Price Target to $10Benzinga · 9/30/2026
- Capitalize on Drug Discovery Informatics: Benchmark Schrödinger, Certara, Dotmatics, Thermo Fisher and BIOVIA to Accelerate R&D ROI and Secure Market AdvantageYahoo · 9/22/2026
- Capitalize on Biosimulation’s R&D Disruption: Benchmark Certara, Simulations Plus, Dassault Systèmes, Schrödinger and Applied BioMath to Accelerate Drug Pipelines and Secure ROIYahoo · 9/22/2026
- Certara (CERT) Slashes Jobs While Doubling Down On Software GrowthYahoo · 9/14/2026
Insider Activity
Insider Actions →- Mohammed Faiz · September 1, 2026 · Grant63.5K
- Daniel Corcoran · June 1, 2026 · Option Exercise14.9K
- Daniel Corcoran · June 1, 2026 · Option Exercise7.9K
- Daniel Corcoran · June 1, 2026 · Tax Withholding7.9K @ $5.82
- Daniel Corcoran · June 1, 2026 · Tax Withholding4.2K @ $5.82
- Rona Anhalt · June 1, 2026 · Option Exercise7.1K
- Rona Anhalt · June 1, 2026 · Tax Withholding2.2K @ $5.82
- Nancy Killefer · May 14, 2026 · Option Exercise15.8K
- Eran Broshy · May 14, 2026 · Grant33.2K
- Eran Broshy · May 14, 2026 · Option Exercise15.8K
- James E. Cashman III · May 14, 2026 · Grant33.2K
- James E. Cashman III · May 14, 2026 · Option Exercise15.8K
- Rosemary A. Crane · May 14, 2026 · Option Exercise15.8K
- Cynthia Collins · May 14, 2026 · Option Exercise15.8K
- Matthew M. Walsh · May 14, 2026 · Grant33.2K
Institutional Ownership
March 31, 2026
- Total shares held
- 128.06M
- Total value held
- $708.30M
- Institutional holders
- 245
- Unknown14.31M
- Unknown8.56M
- Unknown7.81M
- Unknown6.86M
- Unknown5.36M
- Unknown5.27M
- Unknown4.59M
- Unknown4.56M
- Unknown3.94M
- Unknown3.42M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Certara analysts raise price targets, maintain positive outlook
TD Cowen kept its buy rating on Certara and lifted its price target to $11. Barclays also maintained an equal‑weight stance and increased its target to $9. A Yahoo analysis noted the company's fair‑value estimate moving higher as the turnaround gains traction. The upgrades suggest growing confidence among analysts.
Certara analysts raise price targets, maintain positive outlook. TD Cowen kept its buy rating on Certara and lifted its price target to $11. Barclays also maintained an equal‑weight stance and increased its target to $9. A Yahoo analysis noted the company's fair‑value estimate moving higher as the turnaround gains traction. The upgrades suggest growing confidence among analysts.